Shopping Cart 0
Cart Subtotal
USD 0

Northwest Biotherapeutics Inc (NWBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Northwest Biotherapeutics Inc (NW Bio) is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer. The company by utilizing its proprietary technology platform, DCVax, developed a robust pipeline of therapeutic product candidates. DCVax is a personalized immune therapy and consists of therapeutic vaccine which uses patient's own dendritic cells as the therapeutic agent. The product has two components, namely, dendritic cells (immune cells) and antigens (cancer biomarkers). The company's product lines include DCVax-L, for the treatment of glioblastoma multiforme (GBM) brain cancer and metastatic ovarian cancer; DCVax-Direct, for the treatment of all inoperable solid tumor cancers; and DCVax-Prostate, for the treatment of late stage prostate cancer. NW Bio is headquartered in Bethesda, Maryland, the US.

Northwest Biotherapeutics Inc (NWBO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Northwest Biotherapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Equity Offering 13

Northwest Biotherapeutics to Raise Funds in Private Placement of Shares 13

Northwest Biotherapeutics Raises USD12 Million in Private Placement of Preferred Stock and Warrants 14

Northwest Biotherapeutics to Raise USD1.8 Million in Private Placement of Shares and Warrants 15

Northwest Biotherapeutics Raises Funds through Private Placement 16

Northwest Biotherapeutics Raises USD7.5 Million in Private Placement of Shares and Warrants 17

Northwest Biotherapeutics to Raise USD10 Million in Private Placement of Shares and Warrants 19

Northwest Biotherapeutics to Raise USD5.3 Million in Private Placement of Shares 20

Northwest Biotherapeutics to Raise USD3.7 Million in Private Placement of Shares 21

Northwest Biotherapeutics to Raise USD27.6 Million in Private Placement of Shares 22

Northwest Biotherapeutics Raises USD12.6 Million in Private Placement of Shares 23

Northwest Biotherapeutics to Raise USD30 Million in Private Placement of Shares 24

Northwest Biotherapeutics Raises USD40 Million in Private Placement of Shares 25

Northwest Biotherapeutics Raises USD25 Million in Private Placement of Shares 26

Northwest Biotherapeutics Raises USD11.5 Million in Private Placement of Shares 27

Northwest Biotherapeutics Completes Private Placement Of Shares For USD 15 Million 29

Northwest Biotherapeutics Completes Public Offering Of Units For USD 27 Million 30

Northwest Biotherapeutics Completes Private Placement Of Units For USD 15 Million 31

Northwest Biotherapeutics Completes Private Placement Of Shares For USD 10 Million 33

Northwest Biotherapeutics Completes Public Offering Of Shares For USD 14 Million 34

Debt Offering 36

Northwest Biotherapeutics Raises USD17.5 Million in Private Placement of 5% Notes Due 2017 36

Northwest Biotherapeutics Inc-Key Competitors 37

Northwest Biotherapeutics Inc-Key Employees 38

Northwest Biotherapeutics Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Legal and Regulatory 40

Oct 25, 2017: NW Bio Reports Favorable Results and Progress In Resolving Lawsuits 40

Product News 42

09/01/2017: DCVax-L Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference 42

06/05/2018: Personalized vaccine may increase long-term survival in people with deadliest form of brain cancer 43

Clinical Trials 44

May 31, 2018: NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO 44

May 29, 2018: NW Bio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax-L for Glioblastoma Brain Cancer 45

Jun 05, 2017: Dr. Marnix Bosch To Present Update on DCVax-L at the ASCO Conference 47

Feb 06, 2017: NW Bio Announces Lifting of Clinical Hold on DCVax-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached 48

Other Significant Developments 49

Oct 17, 2017: NW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Northwest Biotherapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Northwest Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Northwest Biotherapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Northwest Biotherapeutics to Raise Funds in Private Placement of Shares 13

Northwest Biotherapeutics Raises USD12 Million in Private Placement of Preferred Stock and Warrants 14

Northwest Biotherapeutics to Raise USD1.8 Million in Private Placement of Shares and Warrants 15

Northwest Biotherapeutics Raises Funds through Private Placement 16

Northwest Biotherapeutics Raises USD7.5 Million in Private Placement of Shares and Warrants 17

Northwest Biotherapeutics to Raise USD10 Million in Private Placement of Shares and Warrants 19

Northwest Biotherapeutics to Raise USD5.3 Million in Private Placement of Shares 20

Northwest Biotherapeutics to Raise USD3.7 Million in Private Placement of Shares 21

Northwest Biotherapeutics to Raise USD27.6 Million in Private Placement of Shares 22

Northwest Biotherapeutics Raises USD12.6 Million in Private Placement of Shares 23

Northwest Biotherapeutics to Raise USD30 Million in Private Placement of Shares 24

Northwest Biotherapeutics Raises USD40 Million in Private Placement of Shares 25

Northwest Biotherapeutics Raises USD25 Million in Private Placement of Shares 26

Northwest Biotherapeutics Raises USD11.5 Million in Private Placement of Shares 27

Northwest Biotherapeutics Completes Private Placement Of Shares For USD 15 Million 29

Northwest Biotherapeutics Completes Public Offering Of Units For USD 27 Million 30

Northwest Biotherapeutics Completes Private Placement Of Units For USD 15 Million 31

Northwest Biotherapeutics Completes Private Placement Of Shares For USD 10 Million 33

Northwest Biotherapeutics Completes Public Offering Of Shares For USD 14 Million 34

Northwest Biotherapeutics Raises USD17.5 Million in Private Placement of 5% Notes Due 2017 36

Northwest Biotherapeutics Inc, Key Competitors 37

Northwest Biotherapeutics Inc, Key Employees 38

Northwest Biotherapeutics Inc, Subsidiaries 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Northwest Biotherapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Northwest Biotherapeutics Inc (NW Bio) is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer. The company by utilizing its proprietary technology platform, DCVax, developed a robust pipeline of therapeutic product candidates. DCVax is a personalized immune therapy and consists of therapeutic vaccine which uses patient's own dendritic cells as the therapeutic agent. The product has two components, namely, dendritic cells (immune cells) and antigens (cancer biomarkers). The company's product lines include DCVax-L, for the treatment of glioblastoma multiforme (GBM) brain cancer and metastatic ovarian cancer; DCVax-Direct, for the treatment of all inoperable solid tumor cancers; and DCVax-Prostate, for the treatment of late stage prostate cancer. NW Bio is headquartered in Bethesda, Maryland, the US.

Northwest Biotherapeutics Inc (NWBO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Northwest Biotherapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Equity Offering 13

Northwest Biotherapeutics to Raise Funds in Private Placement of Shares 13

Northwest Biotherapeutics Raises USD12 Million in Private Placement of Preferred Stock and Warrants 14

Northwest Biotherapeutics to Raise USD1.8 Million in Private Placement of Shares and Warrants 15

Northwest Biotherapeutics Raises Funds through Private Placement 16

Northwest Biotherapeutics Raises USD7.5 Million in Private Placement of Shares and Warrants 17

Northwest Biotherapeutics to Raise USD10 Million in Private Placement of Shares and Warrants 19

Northwest Biotherapeutics to Raise USD5.3 Million in Private Placement of Shares 20

Northwest Biotherapeutics to Raise USD3.7 Million in Private Placement of Shares 21

Northwest Biotherapeutics to Raise USD27.6 Million in Private Placement of Shares 22

Northwest Biotherapeutics Raises USD12.6 Million in Private Placement of Shares 23

Northwest Biotherapeutics to Raise USD30 Million in Private Placement of Shares 24

Northwest Biotherapeutics Raises USD40 Million in Private Placement of Shares 25

Northwest Biotherapeutics Raises USD25 Million in Private Placement of Shares 26

Northwest Biotherapeutics Raises USD11.5 Million in Private Placement of Shares 27

Northwest Biotherapeutics Completes Private Placement Of Shares For USD 15 Million 29

Northwest Biotherapeutics Completes Public Offering Of Units For USD 27 Million 30

Northwest Biotherapeutics Completes Private Placement Of Units For USD 15 Million 31

Northwest Biotherapeutics Completes Private Placement Of Shares For USD 10 Million 33

Northwest Biotherapeutics Completes Public Offering Of Shares For USD 14 Million 34

Debt Offering 36

Northwest Biotherapeutics Raises USD17.5 Million in Private Placement of 5% Notes Due 2017 36

Northwest Biotherapeutics Inc-Key Competitors 37

Northwest Biotherapeutics Inc-Key Employees 38

Northwest Biotherapeutics Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Legal and Regulatory 40

Oct 25, 2017: NW Bio Reports Favorable Results and Progress In Resolving Lawsuits 40

Product News 42

09/01/2017: DCVax-L Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference 42

06/05/2018: Personalized vaccine may increase long-term survival in people with deadliest form of brain cancer 43

Clinical Trials 44

May 31, 2018: NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO 44

May 29, 2018: NW Bio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax-L for Glioblastoma Brain Cancer 45

Jun 05, 2017: Dr. Marnix Bosch To Present Update on DCVax-L at the ASCO Conference 47

Feb 06, 2017: NW Bio Announces Lifting of Clinical Hold on DCVax-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached 48

Other Significant Developments 49

Oct 17, 2017: NW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Northwest Biotherapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Northwest Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Northwest Biotherapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Northwest Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Northwest Biotherapeutics to Raise Funds in Private Placement of Shares 13

Northwest Biotherapeutics Raises USD12 Million in Private Placement of Preferred Stock and Warrants 14

Northwest Biotherapeutics to Raise USD1.8 Million in Private Placement of Shares and Warrants 15

Northwest Biotherapeutics Raises Funds through Private Placement 16

Northwest Biotherapeutics Raises USD7.5 Million in Private Placement of Shares and Warrants 17

Northwest Biotherapeutics to Raise USD10 Million in Private Placement of Shares and Warrants 19

Northwest Biotherapeutics to Raise USD5.3 Million in Private Placement of Shares 20

Northwest Biotherapeutics to Raise USD3.7 Million in Private Placement of Shares 21

Northwest Biotherapeutics to Raise USD27.6 Million in Private Placement of Shares 22

Northwest Biotherapeutics Raises USD12.6 Million in Private Placement of Shares 23

Northwest Biotherapeutics to Raise USD30 Million in Private Placement of Shares 24

Northwest Biotherapeutics Raises USD40 Million in Private Placement of Shares 25

Northwest Biotherapeutics Raises USD25 Million in Private Placement of Shares 26

Northwest Biotherapeutics Raises USD11.5 Million in Private Placement of Shares 27

Northwest Biotherapeutics Completes Private Placement Of Shares For USD 15 Million 29

Northwest Biotherapeutics Completes Public Offering Of Units For USD 27 Million 30

Northwest Biotherapeutics Completes Private Placement Of Units For USD 15 Million 31

Northwest Biotherapeutics Completes Private Placement Of Shares For USD 10 Million 33

Northwest Biotherapeutics Completes Public Offering Of Shares For USD 14 Million 34

Northwest Biotherapeutics Raises USD17.5 Million in Private Placement of 5% Notes Due 2017 36

Northwest Biotherapeutics Inc, Key Competitors 37

Northwest Biotherapeutics Inc, Key Employees 38

Northwest Biotherapeutics Inc, Subsidiaries 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Northwest Biotherapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.